Nature Medicine 2017-11-13

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies

Paul M Maciocia, Patrycja A Wawrzyniecka, Brian Philip, Ida Ricciardelli, Ayse U Akarca, Shimobi C Onuoha, Mateusz Legut, David K Cole, Andrew K Sewell, Giuseppe Gritti, Joan Somja, Miguel A Piris, Karl S Peggs, David C Linch, Teresa Marafioti, Martin A Pule

Index: 10.1038/nm.4444

Full Text: HTML

Abstract

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies, Published online: 13 November 2017; doi:10.1038/nm.4444NatureArticleSnippet(type=short-summary, markup= Pule and colleagues identify the TCR β-chain constant region as a new target for chimericantigen receptor (CAR) T cells in treatment of T cell cancers while potentially preserving a healthyT cell repertoire. They demonstrate that anti-TCRB1 CAR T cells eliminate cancerousTCRB1+ T cells while sparing nearly one-third of normal TCRB2+ T cells., isJats=true)